Sinha Vikas — SEC Form 4 filings
SEC reporting owner CIK 1337845. 30 Form 4 filings on record with FilingPulse; latest filed 2026-04-20.
Transaction summary — filings shown
Covers all 30 filings on record, filed 2024-01-25 to 2026-04-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 30 legs across 24 filings — 435,135 shares, $4,446,807 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 26.
- Largest priced transaction: sale of 160,000 shares @ $9.39 ($1,502,928) in Verona Pharma plc, filed 2025-05-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Verona Pharma plc (VRNA) | Director | 7 | — | 6 legs · 344,328 sh · $3,165,558 | 22 |
| Scholar Rock Holding Corp (SRRK) | Chief Financial Officer | 5 | — | 2 legs · 27,165 sh · $1,231,509 | 4 |
| Allovir, Inc. (ALVR) | See Remarks, Director, 10% owner | 18 | — | 22 legs · 63,642 sh · $49,740 | — |
Form 4 filings — Sinha Vikas
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-20 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 10,410 @ $49.57 | EDGAR |
| 2026-02-11 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 47,021 @ $0 | EDGAR |
| 2026-01-15 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 16,755 @ $42.70 | EDGAR |
| 2025-10-08 | 4 | Verona Pharma plc (VRNA) | Disposition to issuer (D): 94,112 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 384 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +2 more | EDGAR |
| 2025-08-05 | 4 | Verona Pharma plc (VRNA) | Option exercise (M): 24,000 @ $0 · Sale (S): 4,328 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4/A | Verona Pharma plc (VRNA) | Option exercise (M): 120,384 @ $1.70 · Sale (S): 120,384 @ $8.92 · Option exercise (M): 39,616 @ $0.50 · Sale (S): 39,616 @ $8.92 · Option exercise (M): 120,384 (derivative) @ $0 · Option exercise (M): 39,616 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Verona Pharma plc (VRNA) | Option exercise (M): 160,000 @ $0.50 · Sale (S): 160,000 @ $9.39 · Option exercise (M): 160,000 (derivative) @ $0 | EDGAR |
| 2025-05-06 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 110,067 (derivative) @ $0 | EDGAR |
| 2025-05-01 | 4 | Verona Pharma plc (VRNA) | Option exercise (M): 15,048 @ $1.70 · Sale (S): 15,048 @ $8.92 · Option exercise (M): 4,952 @ $0.50 · Sale (S): 4,952 @ $8.92 · Option exercise (M): 15,048 (derivative) @ $0 · Option exercise (M): 4,952 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Verona Pharma plc (VRNA) | Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 100,000 @ $0 · Grant/award (A): 500,000 @ $0 | EDGAR |
| 2025-02-24 | 4 | Allovir, Inc. (ALVR) | Sale (S): 303 @ $10.08 | EDGAR |
| 2025-01-27 | 4 | Allovir, Inc. (ALVR) | Sale (S): 116 @ $9.45 · Sale (S): 13 @ $9.94 | EDGAR |
| 2025-01-13 | 4 | Allovir, Inc. (ALVR) | Sale (S): 979 @ $0.44 | EDGAR |
| 2024-11-20 | 4 | Allovir, Inc. (ALVR) | Sale (S): 3,186 @ $0.55 | EDGAR |
| 2024-11-06 | 4 | Allovir, Inc. (ALVR) | Sale (S): 5,136 @ $0.86 | EDGAR |
| 2024-10-23 | 4 | Allovir, Inc. (ALVR) | Sale (S): 1,546 @ $0.78 · Sale (S): 1,882 @ $0.77 | EDGAR |
| 2024-10-04 | 4 | Allovir, Inc. (ALVR) | Sale (S): 940 @ $0.81 | EDGAR |
| 2024-08-20 | 4 | Allovir, Inc. (ALVR) | Sale (S): 3,159 @ $0.76 | EDGAR |
| 2024-08-07 | 4 | Allovir, Inc. (ALVR) | Sale (S): 5,251 @ $0.73 | EDGAR |
| 2024-07-23 | 4 | Allovir, Inc. (ALVR) | Sale (S): 1,542 @ $0.75 · Sale (S): 1,858 @ $0.74 | EDGAR |
| 2024-07-03 | 4 | Allovir, Inc. (ALVR) | Sale (S): 939 @ $0.72 | EDGAR |
| 2024-05-21 | 4 | Allovir, Inc. (ALVR) | Sale (S): 3,143 @ $0.75 | EDGAR |
| 2024-05-07 | 4 | Allovir, Inc. (ALVR) | Sale (S): 4,957 @ $0.80 | EDGAR |
| 2024-04-30 | 4 | Verona Pharma plc (VRNA) | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2024-04-23 | 4 | Allovir, Inc. (ALVR) | Sale (S): 1,521 @ $0.75 · Sale (S): 1,857 @ $0.75 | EDGAR |
| 2024-04-04 | 4 | Allovir, Inc. (ALVR) | Sale (S): 885 @ $0.77 | EDGAR |
| 2024-02-22 | 4 | Allovir, Inc. (ALVR) | Sale (S): 2,893 @ $0.70 | EDGAR |
| 2024-02-06 | 4 | Allovir, Inc. (ALVR) | Sale (S): 18,331 @ $0.67 | EDGAR |
| 2024-01-25 | 4 | Allovir, Inc. (ALVR) | Sale (S): 3,205 @ $0.67 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1337845 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →